Investor Presentaiton
Appendix (Financial Results for FY2022)
Financial Position
B/S
Billions of yen
As of March
2022
As of March
Change
2023
Assets
1,308.0
1,134.7
(173.3)
Impairment losses
Goodwill Intangible assets
593.8
538.7
Other financial assets (Non-current)
115.8
134.0
(55.1)
18.2
Trade and other receivables
151.4
95.9
(55.5)
Cash and deposit / Short-term loan receivable
230.2
153.5
(76.7)
Liabilities
634.4
728.0
93.5
Increase due to changes in valuation of securities
Decrease due to loss of exclusivity of LATUDAⓇ
Payment for making Myovant a wholly owned
subsidiary
Bonds and borrowings
269.0
334.7
65.7
Fair value of contingent consideration
4.4
1.5
(Other financial liaiabilities)
Deferred tax liabilities
Income taxes payable
Equity
Attributable to owners of the parent
(Ratio of equity attributable to owners of the parent)
to total assets
(2.9)
Financing to make Myovant a wholly owned
subsidiary
26.6
36.5
10.0
7.6
24.1
16.5
673.6
406.8
(266.8)
607.9
406.7
(201.1)
Impact of making Myovant a wholly owned
subsidiary
46.5%
35.8%
C/F
FY2021
FY2022
Change
Operating CF
31.2
11.9
(19.3)
Investment CF
(18.3)
52.4
Financial CF
(21.4)
(146.8)
70.7
(125.4)
Cash and cash equivalents
203.0
143.5
(59.5)
Proceeds from sales of the share of Sumitomo
Pharma Food & Chemical Co., Ltd. and
intangible assets etc.
Decrease in payment for making Myovant a
wholly owned subsidiary
(Operating funds)
234.9
158.0
(76.9)
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 22View entire presentation